Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ajd.12855 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Survival Outcomes of 997 Patients With Eyelid Sebaceous Carcinoma in the National Cancer Database.
J Craniofac Surg
December 2024
Department of Ophthalmology, University of CaliforniaIrvine, Irvine, CA.
Objectives: This study aimed to characterize the survival of patients with sebaceous carcinoma (SC) of the eyelids according to demographics and other variables.
Methods: Patients with SC of the eyelids from 2004 to 2017 were identified in the National Cancer Database. Demographic and clinical covariates were assessed.
Sebaceous gland hyperplasia is a benign cutaneous entity commonly seen in older men. Occasionally, it can develop in young patients on immunosuppression with cyclosporine or in adolescent boys in the peripubertal age group. It is extremely rare in young children with no reports of eyelid involvement.
View Article and Find Full Text PDFOil Red O: A Useful Adjunctive Stain for Sebaceous Carcinoma of the Eyelid Margin.
Dermatol Surg
December 2024
Department of Dermatology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Comparative educational effectiveness of AI generated images and traditional lectures for diagnosing chalazion and sebaceous carcinoma.
Sci Rep
November 2024
Department of Ophthalmology, Cancer Institute Hospital, Tokyo, Japan.
Sebaceous carcinoma is difficult to distinguish from chalazion due to their rarity and clinicians' limited experience. This study investigated the potential of AI-generated image training to improve diagnostic skills for these eyelid tumors compared to traditional video lecture-based education. Students from Orthoptics, Optometry, and Vision Research (n = 55) were randomly assigned to either an AI-generated image training group or a traditional video lecture group.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!